Company · Biotech and pharma
Precision therapies for inflammatory and fibrotic diseases
Melbourne, VIC
Every published round CERTA TherapeuticsTreatment of fibrotic diseases took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies CERTA TherapeuticsTreatment of fibrotic diseases has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for CERTA TherapeuticsTreatment of fibrotic diseases, as distinct from the investments it has made.
Companies CERTA TherapeuticsTreatment of fibrotic diseases has backed that another company then bought. An exit for the holding, not a deal CERTA TherapeuticsTreatment of fibrotic diseases did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of CERTA TherapeuticsTreatment of fibrotic diseases is recorded as having been acquired. | ||||
Companies CERTA TherapeuticsTreatment of fibrotic diseases acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| OccuRx | Acquisition | 19 Dec 2024 | - | Brandon BioCatalyst, Brandon Capital |
| Name | Role | Sources |
|---|---|---|
| Professor Darren Kelly | CEO · Founder | Brandon BioCatalyst, Brandon Capital (19 Dec 2024), Brandon Capital (16 Nov 2023) |
| Dr Chris Nave | Chair (former) | Brandon BioCatalyst, Brandon Capital |
Stories naming CERTA TherapeuticsTreatment of fibrotic diseases. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.